Literature DB >> 9775416

Medical treatment and medical side effects in urinary incontinence in the elderly.

J W Thüroff1, E Chartier-Kastler, J Corcus, J Humke, U Jonas, H Palmtag, E A Tanagho.   

Abstract

Entities:  

Mesh：

Year:  1998        PMID： 9775416     DOI： 10.1007/pl00014139

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  10 in total

1.  The effects of reformulation: improved therapeutic index.

Authors:  Scott MacDiarmid; Bobby W Sandage; Bimal K Malhotra
Journal:  Curr Urol Rep       Date:  2008-11       Impact factor: 3.092

2.  Summary of scientific evidence.

Authors: 
Journal:  Occas Pap R Coll Gen Pract       Date:  2002-02

Review 3.  Pharmacotherapy for nocturia in the elderly patient.

Authors:  Ragnar Asplund
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

4.  The evolution of transdermal/ topical overactive bladder therapy and its benefits over oral therapy.

Authors:  Scott A Macdiarmid
Journal:  Rev Obstet Gynecol       Date:  2009

Review 5.  [The medication-induced dysfunction of the urinary bladder].

Authors:  T Schneider; H Rübben; M C Michel
Journal:  Urologe A       Date:  2003-12       Impact factor: 0.639

Review 6.  [Overactive bladder--treatment with antimuscarinic agents].

Authors:  K Höfner
Journal:  Urologe A       Date:  2003-05-20       Impact factor: 0.639

7.  The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy.

Authors:  Scott A Macdiarmid
Journal:  Rev Urol       Date:  2009

Review 8.  An update on the use of transdermal oxybutynin in the management of overactive bladder disorder.

Authors:  Joshua A Cohn; Elizabeth T Brown; W Stuart Reynolds; Melissa R Kaufman; Douglas F Milam; Roger R Dmochowski
Journal:  Ther Adv Urol       Date:  2016-01-19

Review 9.  Approach to urinary incontinence in women. Diagnosis and management by family physicians.

Authors:  Barbara O'Neil; Donna Gilmour
Journal:  Can Fam Physician       Date:  2003-05       Impact factor: 3.275

10.  Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.

Authors:  V W Nitti; V Khullar; P van Kerrebroeck; S Herschorn; J Cambronero; J C Angulo; M B Blauwet; C Dorrepaal; E Siddiqui; N E Martin
Journal:  Int J Clin Pract       Date:  2013-05-21       Impact factor: 2.503
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.